J&J Drops Alligator’s MAb ADC-1013 After Reviewing Combination Data
Executive Summary
The anti-CD40 antibody underperformed in some preclinical cancer combination studies, leading J&J to prioritize other assets. Alligator Bioscience will now advance ADC-1013 while seeking a new partner.
You may also be interested in...
CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
HBW US Market News: FTC Returns 'Free Trial' Losses, Old Spice Targets 'Meat Sweats,' More
FTC returns more than $5.4m to more than 100,000 consumers from "free trial" scam;" Hood College names Nutrition Science Program's founding director; Cremer introduces gummy-counting machine; Herbalife renovates LA headquarters; Arby's and Old Spice team up to fight "meat sweats."
Takeda Moves Takhzyro Toward Dominant Position In Pediatric HAE
The company announced data from the Phase III SPRING study of Takhzyro in children aged 2-11; there is no approved long-term prophylactic therapy for children under 6.